A number of glycomic and glycoproteomic studies have also looked beyond PSA for prostate cancer-specific glycosylation changes in a variety of clinical samples, including urine, seminal fluid, blood plasma/serum and tissue24. This evidence concerns the gene PROS1 and prostate carcinoma.